US 10,238,652 B2Granted

Compounds for treatment of cancer

AssigneeCuregenix, Inc.

InventorSongzhu An

Life of this patent

Estimating the term…

Abstract

The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

Claims17

Dependent claims

A method for treating cancer characterized by expression of an R-spondin fusion in a subject that has been diagnosed as having an R-spondin fusion and has been diagnosed with the cancer being treated, comprising:

administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a WNT signaling inhibitor, wherein the WNT signaling inhibitor is a small organic molecule, and wherein the WNT signaling inhibitor inhibits porcupine (PORCN).

Dependencies are inferred from the claim text.

Facts

Application: 15/617,988Filed 8 Jun 2017 · continuation
Priority: 12 Mar 2013
Published: US 2017/0304302 A126 Oct 2017
Granted: 26 Mar 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/4375
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring…
A61K 31/444
Containing further heterocyclic ring systems: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K 31/472
Quinolines; Isoquinolines: non-condensed isoquinolines, e.g. papaverine

Family

Application61/777,427Us provisional application · filed 12 Mar 2013
PCT/US2014/024885Parent of this continuation · filed 12 Mar 2014
US 2017/0304302 A1Pre-grant publication · published 26 Oct 2017
Application14/772,337Parent of this continuation
US 9,713,612 B2Parent of this continuation
US 2016/0000780 A1Published application
US 10,238,652 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Facts

Application

15/617,988Filed 8 Jun 2017 · continuation

Priority

12 Mar 2013

Published

US 2017/0304302 A126 Oct 2017

Granted

26 Mar 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/4375
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring…
A61K 31/444
Containing further heterocyclic ring systems: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K 31/472
Quinolines; Isoquinolines: non-condensed isoquinolines, e.g. papaverine

Family

Application61/777,427Us provisional application · filed 12 Mar 2013

PCT/US2014/024885Parent of this continuation · filed 12 Mar 2014

US 2017/0304302 A1Pre-grant publication · published 26 Oct 2017

Application14/772,337Parent of this continuation

US 9,713,612 B2Parent of this continuation

US 2016/0000780 A1Published application

US 10,238,652 B2This patent

From the US filing history. Foreign family members aren’t listed.